Metastatik Mesane Kanserinde Sistemik Tedaviler
Özet
Mesane kanseri tanısı konulan hastaların yaklaşık %5'i tanı anında metastatiktir. Mesane kanseri lenfatik ve hematojen yollarla, en sık olarak akciğerlere, kemiğe, karaciğere, beyne metastaz yapar. Mesane kanseri kemosensitiftir. Radyolojik yanıt oranları faz II klinik çalışmalarda %70-80 kadarken, faz III klinik çalışmalarda yanıt oranları genellikle %50 civarındadır. Kemosensitif olmasına karşın kemoterapinin yanıt süresi ortalama 4-6 ay arasındadır. Klinik uygulamalara yeni hedefe yönelik tedaviler girdikçe, hastalığa yanıt süresini uzayacağı ve sonuç olarak hayatta kalmada gerçek bir değişime dönüşeceği umulmaktadır.
Referanslar
(C)ancer Stat Facts: Bladder Cancer. NIH NCI: Surveillance, Epidemiology, and End Results Program; 2023. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed February 8, 2024)
Ross JS, Wang K, Khaira D ve diğerleri. Klinik olarak ilerlemi ürotelyal karsinom vakalarının 295'inin kapsamlı genomiprofili idrar kesesi klinik olarak önemli genomik değişikliklerin yüksek sıklığını ortaya koymaktadır. Kanser 2016;122:702-711
Gupta S, Sonpavde G, Grivas P, et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC) [abstract].Journal of Clinical Oncology 2019;37:451-451. Available at:https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.451
Yagoda A, Watson RC, Gonzalez-Vitale JC, et al. Cis-dichlorodiammineplatinum(II) in advanced bladder cancer. Cancer Treat Rep 1976;60(7):917–923 ),
Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, ve doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997;15(7):2564–2569
Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, ve vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985;3(11):1463–1470.179
Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC ve CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol, 1990;8(6):1050–1055
von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine ve cisplatin versus methotrexate, vinblastine, doxorubicin, ve cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–3077.
Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18(9):1921–1927
von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine ve cisplatin versus methotrexate, vinblastine, doxorubicin, ve cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–3077. Roberts JT, von der Maase H, Sengelov L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin ve methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced ve metastatic bladder cancer. Ann Oncol 2006;17(Suppl 5):v118–v122.
Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014;32:1895-1901. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24821881
ternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, ve cisplatin (MVAC) chemotherapy ve recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research ve Treatment of Cancer protocol no. 30924. J Clin Oncol 2001;19(10):2638–2646.
Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937-940. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11844814
De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin ve methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: Phase II—results of EORTC study 30986. J Clin Oncol 2009;27(33): 5634– 5639
Meluch AA, Greco FA, Burris HA, 3rd, et al. Paclitaxel ve gemcitabine che-
motherapy for advanced transitional-cell carcinoma of the urothelial tract:A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001;19(12):3018–3024.
Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine ve
docetaxel therapy in patients with advanced urothelial carcinoma. Cancer
2003;98(9):1863–1869.194
Turkolmez K, Beduk Y, Baltaci S, et al. Gemcitabine plus vinorelbine che-motherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur Urol 2003;44(6):682–686.,
Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin pluspembrolizumab in previously untreated advanced urothelial cancer. JClin Oncol 2023;41:22-31.
Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin andpembrolizumab in untreated advanced urothelial cancer. N Engl J Med
van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plusgemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med
2023;389:1778-1789.
Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads toclinical activity in metastatic bladder cancer. Nature 2014;515(7528): 558–562. 202
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patientswith locally advanced ve metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multi-centre, phase 2 trial. Lancet 2016;387(10031):1909–1920.
208 Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy foradvanced urothelial carcinoma. N Engl J Med 2017;376(11): 1015–1026.
Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: A phaseII open-label study of sacituzumab govitecan in patients with metastaticurothelial carcinoma progressing after platinum-based chemotherapy291
U.S. Food & Drug Administration. Prescribing information. Fam-trastuzumab deruxtecan-nxki for injection, for intravenous use. 2024.Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Accessed April 29, 2024.Fam-trastuzumab deruxtecan,
Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and Safetyof Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II
Trial. J Clin Oncol 2024;42:47-58. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37870536.
U.S. Food & Drug Administration. FDA approves erdafitinib forlocally advanced or metastatic urothelial carcinoma. 2024. Available at:https://www.fda.gov/drugs/resources-information-approved-drugs/fda- approves-erdafitinib-locally-advanced-or-metastatic-urothelial- carcinoma. Accessed February 6, 2024
